

29 Jun 2020 |

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

Join us for a quick audio roundup of five useful things to know from *Scrip's* recent coverage of the global biopharmaceutical industry.

This new microcast provides a brief audio tour around *Scrip's* Five Must-Know Things, in this episode for the week ended 26 June.

On the agenda this time are [Pfizer Inc.](#) and [Sanofi's](#) coronavirus development plans and policies, what increased use of dexamethasone might mean for Indian pharma, [Boehringer Ingelheim International GmbH's](#) M&A strategy, and an infographic on the state of global biopharma R&D.

Stories mentioned in this episode:

(Also see "[Pfizer's Bourla On COVID-19 Vaccine: 'There Is No ROI That Will Drive Our Decision'](#)" - Scrip, 22 Jun, 2020.)

(Also see "[Sanofi Confident Of 'Tortoise And Hare' COVID-19 Vaccine Strategy'](#)" - Scrip, 23 Jun, 2020.)

(Also see "[Is Dexamethasone The Next HCQ For Indian Pharma?](#)" - Scrip, 19 Jun, 2020.)

(Also see "[Boehringer's Philosophy Of Deal-Making: A Conversation With Ioannis Sapountzis And Scott DeWire](#)" - Scrip, 19 Jun, 2020.)

(Also see "[The 2020 Worldwide Pharma & Biotech Industry R&D Scene](#)" - Scrip, 24 Jun, 2020.)

[Click here to explore this interactive content online](#) ✨

